Study guide

Respiratory Distress Syndrome (RDS), Surfactant Therapy, and Bronchopulmonary Dysplasia

EBP-EAP Examination in Paediatrics Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Governance, Ethics & Child Safeguarding

EBP-EAP Format, Delivery, Scoring, and Clinical Vignette Strategy Paediatric Ethics, Consent/Assent, Gillick Competence, and Patient Safety Child Protection, Physical/Emotional Abuse, Neglect, and Non-Accidental Injury (NAI)

2 Chapter 2: Neonatal Transition, Resuscitation & Prematurity

Delivery Room Care, Apgar Scoring, and Neonatal Resuscitation Algorithm Respiratory Distress Syndrome (RDS), Surfactant Therapy, and Bronchopulmonary Dysplasia Perinatal Asphyxia, HIE Sarnat Staging, and Therapeutic Hypothermia Protocol

3 Chapter 3: Neonatal Morbidities, Jaundice & Congenital Infections

Unconjugated vs Conjugated Hyperbilirubinemia, Phototherapy Thresholds, and Exchange Transfusion Early- vs Late-Onset Sepsis, Group B Streptococcus, and Congenital TORCH Infections NEC Diagnosis/Bell Staging, Neonatal Hypoglycaemia, and Newborn Bloodspot Screening

4 Chapter 4: Acute Paediatric Emergencies & Critical Care

EPLS/PALS Structured Approach, Types of Shock, and Weight-Based Fluid Boluses Clinical Diagnostic Criteria, Intramuscular Adrenaline Dosing, and Refractory Anaphylaxis 5-Minute Time-Critical Anticonvulsant Protocol and Status Epilepticus Care Common Toxidromes (Paracetamol, Iron, Caustics, Button Batteries) and Decontamination

5 Chapter 5: Paediatric Respiratory Medicine

Stridor Differential, Croup (Westley Score & Dexamethasone), and Epiglottitis RSV Pathogenesis, Supportive Management, Oxygen/High-Flow Criteria, and Futility of Bronchodilators/Steroids European/BTS Guidelines on Chronic Stepwise Control and Acute Severe Exacerbation Management Community-Acquired Pneumonia Etiology, Parapneumonic Effusion/Empyema, and Cystic Fibrosis Pulmonary Exacerbations

6 Chapter 6: Paediatric Cardiology

Acyanotic vs Cyanotic Congenital Heart Disease: Ductal Patency, Shunt Lesions, and Emergency Stabilization Paediatric Murmurs and Arrhythmias: Innocent vs Pathological Murmurs, SVT, and Resuscitation Protocols Acquired Heart Disease: Kawasaki Disease, Coronary Aneurysm Prevention, and Acute Rheumatic Fever

7 Chapter 7: Paediatric Gastroenterology, Hepatology & Nutrition

Dehydration Severity Assessment, Oral Rehydration Therapy (ORT), and Intravenous Fluid Protocols ESPGHAN Coeliac Diagnostic Criteria (Biopsy-Sparing Pathway) and Paediatric Crohn's/Ulcerative Colitis Breastfeeding, Formula Selection, Cow's Milk Protein Allergy (CMPA), GERD vs GOR, and Faltering Growth Prolonged Neonatal Jaundice Workup, Biliary Atresia Red Flags, and Acute Hepatitis/Liver Failure

8 Chapter 8: Paediatric Nephrology, Fluids & Electrolyte Balance

Paediatric UTI Diagnosis, Imaging Criteria (Ultrasound/DMSA/MCUG), and Vesicoureteral Reflux Minimal Change Nephrotic Syndrome (Steroid Regimen & Complications) vs Acute Post-Infectious Glomerulonephritis Paediatric AKI (pRIFLE/KDIGO), Haemolytic Uraemic Syndrome (HUS), and Hyperkalaemia/Dysnatraemia Management

9 Chapter 9: Paediatric Endocrinology & Inborn Errors of Metabolism

Paediatric DKA Protocol (ISPAD/European Fluid & Insulin Guidelines, Cerebral Oedema Prevention) and T1DM Maintenance Congenital Hypothyroidism Screening & Levothyroxine, Congenital Adrenal Hyperplasia (21-Hydroxylase Deficiency), and Adrenal Crisis Short Stature Workup, Precocious vs Delayed Puberty, and Approach to Suspected Inborn Errors of Metabolism (IEM)

10 Chapter 10: Paediatric Neurology, Neurodevelopment & Mental Health

Simple vs Complex Febrile Seizures, Childhood Epilepsy Syndromes (Absence, Infantile Spasms, Benign Rolandic), and Antiseizure Medications Red Flags for Raised Intracranial Pressure (ICP), Brain Tumours, Migraine vs Tension Headache Acute Bacterial Meningitis (LP Contraindications, Ceftriaxone, Dexamethasone) and Viral Encephalitis (Aciclovir) Developmental Milestones (Gross Motor, Fine Motor/Vision, Speech/Language, Social), Autism Spectrum, ADHD, and Cerebral Palsy

11 Chapter 11: Paediatric Haematology & Oncology

Microcytic Anaemia (Iron Deficiency vs Thalassaemia Trait/Mentzer Index), Haemolytic Anaemias (Spherocytosis, G6PD) Sickle Cell Crises (Vaso-occlusive, Acute Chest Syndrome, Stroke Prevention), Immune Thrombocytopenia (ITP), and Haemophilia A/B Acute Lymphoblastic Leukaemia (ALL), Neuroblastoma, Wilms Tumour, and Management of Febrile Neutropenia

12 Chapter 12: Paediatric Infectious Diseases, Immunology & Allergy

Common Childhood Exanthems: Clinical Morphology, Timelines, Complications, and Management Paediatric Tuberculosis, Sepsis Six in Children, and Acute Osteoarticular Infections Pediatric Allergy, Atopic Eczema, Food Hypersensitivity, and Desensitization Primary Immunodeficiencies, Warning Signs, Live Vaccine Contraindications, and European Immunisation Schedules

13 Chapter 13: Paediatric Musculoskeletal, Dermatology & Surgical Conditions

The Limping Child, Septic Arthritis vs Transient Synovitis, and Juvenile Idiopathic Arthritis Henoch-Schönlein Purpura, Kawasaki Disease vs MIS-C, Infantile Haemangiomas, and Common Pediatric Eruptions Acute Appendicitis, Intussusception, Pyloric Stenosis, Testicular Torsion, and Incarcerated Hernia

14 Chapter 14: Research Methods, Biostatistics & Evidence-Based Paediatrics

Study Designs, Causality, Bias, and Epidemiological Measures in Paediatrics Diagnostic Test Accuracy, Statistical Inference, and Hypothesis Testing Systematic Reviews, Meta-Analysis, Decision Analysis, and Paediatric Research Ethics

15 Chapter 15: Paediatric Ophthalmology & ENT Disorders

Paediatric Vision Assessment, Refractive Disorders, Strabismus, and Leukocoria Ocular Emergencies, Orbital Infections, ROP, and Systemic Manifestations Paediatric Otolaryngology: Otitis Media, Hearing Impairment, and Upper Airway Conditions

16 Chapter 16: Paediatric Sports Medicine & Musculoskeletal Health

Skeletal Maturity, Physeal Injuries, Apophysitis, and Overuse Syndromes Paediatric Sports Concussion, Second Impact Syndrome, and Return-to-Play Protocols Pre-Participation Screening, Physical Activity Guidelines, and Chronic Disease Clearance

17 Chapter 17: Adolescent Medicine & Healthcare Transition

Biopsychosocial Development, Pubertal Staging, and Adolescent Communication Adolescent Confidentiality, Risk Behaviours, Reproductive Health, and Eating Disorders Chronic Illness in Adolescence and Structured Healthcare Transition

18 Chapter 18: Paediatric Genetics, Dysmorphology & Clinical Genomics

Patterns of Inheritance, Non-Mendelian Mechanisms, and Pedigree Construction Clinical Dysmorphology, Chromosomal Aneuploidies, and Microdeletion Syndromes Genetic Testing Technologies, Prenatal Diagnosis, and Genetic Counselling Ethics

19 Chapter 19: Paediatric Mental Health, Behaviour & Community Medicine

Cognitive Development, Attachment, Screening, and Common Emotional Disorders Regulatory Disorders, Neurodevelopmental Behavioural Conditions, and Psychosomatic Illness Community Child Healthcare Structures, Disability Coordination, and Child Advocacy

Respiratory Distress Syndrome (RDS), Surfactant Therapy, and Bronchopulmonary Dysplasia

Key Takeaways Explain This Topic AI

Respiratory distress syndrome (RDS) stems from developmental surfactant deficiency in type II pneumocytes, producing high alveolar surface tension, diffuse microatelectasis, and characteristic reticulogranular ground-glass opacities with air bronchograms on chest radiography.

Antenatal corticosteroids reduce mortality, RDS and IVH when preterm birth is imminent and active neonatal care is planned. Standard regimens are betamethasone 12 mg IM twice 24 hours apart or dexamethasone 6 mg IM four times 12 hours apart; routine European treatment is before 34 weeks.

Early non-invasive stabilization using continuous positive airway pressure (CPAP 6–8 cmH2O) in the delivery room preserves endogenous surfactant and prevents ventilator-induced lung injury compared to routine immediate intubation.

Give surfactant early for worsening RDS, preferably by a thin catheter during spontaneous breathing on CPAP. The European consensus uses an FiO2 threshold of at least 0.30 on non-invasive support at ≥6 cmH2O; poractant alfa 200 mg/kg is the preferred initial dose.

Bronchopulmonary dysplasia (BPD) reflects an arrest of alveolar and microvascular development in extremely preterm infants; high-risk preterm infants require post-discharge immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab or nirsevimab.

Last updated: November 2026

Surfactant Physiology and Pathogenesis of RDS

Respiratory Distress Syndrome (RDS), historically designated hyaline membrane disease, is the primary respiratory morbidity affecting preterm infants. The condition is driven by developmental deficiency in both the quantity and biochemical composition of pulmonary surfactant.

Biochemical Composition of Pulmonary Surfactant

Surfactant is an amphiphilic lipoprotein complex produced by type II alveolar pneumocytes :

Phospholipids (80%): Predominantly dipalmitoylphosphatidylcholine (DPPC) , also termed disaturated phosphatidylcholine. DPPC molecules arrange themselves at the air-liquid interface with their hydrophobic fatty acid tails projecting into the alveolar gas and hydrophilic head groups submerged in the hypophase, displacing water molecules.

Neutral Lipids (10%): Mainly unesterified cholesterol, which modulates the fluidity and lateral mobility of the lipid monolayer.

Surfactant Proteins (10%):

SP-B and SP-C (Hydrophobic Proteins): Essential for biophysical function. They facilitate the rapid insertion, spreading, and reorganization of DPPC into a tightly packed surface monolayer during expiration, lowering alveolar surface tension to near 0 mN/m . Congenital SP-B deficiency is an autosomal recessive, lethal condition causing intractable neonatal respiratory failure.

SP-A and SP-D (Hydrophilic Collectins): Mediate innate pulmonary host defense by binding bacterial, fungal, and viral pathogens, facilitating phagocytosis by alveolar macrophages. They do not lower surface tension directly.

Development and Regulation

Type II pneumocytes synthesize surfactant components within the endoplasmic reticulum and Golgi apparatus, packaging them into specialized storage organelles termed lamellar bodies . Surfactant synthesis begins around 20 to 24 weeks gestation, but functional biochemical maturity and extensive exocytosis into the alveolar space surge markedly after 32 to 34 weeks gestation , driven by fetal cortisol, thyroid hormones, and mechanical stretch.

Laplace's Law and Alveolar Instability

The biophysical behavior of the alveolus is governed by Laplace's Law for spherical structures:

P = 2 T r P = \frac{2T}{r} P = r 2 T ​

Where P P P is the inward collapsing pressure, T T T is the surface tension at the liquid-gas interface, and r r r is the alveolar radius.

In the healthy, surfactant-replete lung , surfactant molecules concentrate tightly as alveolar radius shrinks during expiration, reducing surface tension ( T T T ) toward zero. This preserves alveolar stability and prevents collapse even at low lung volumes.

In surfactant deficiency , surface tension remains constantly high (~70 mN/m). As a consequence, smaller alveoli generate markedly higher collapsing pressures than adjacent larger alveoli, emptying their gas contents into larger units. This produces widespread microatelectasis , loss of functional residual capacity (FRC), intrapulmonary right-to-left shunting, severe ventilation-perfusion ( V / Q V/Q V / Q ) mismatch, and profound hypoxemia.

Low lung compliance ( C = Δ V / Δ P C = \Delta V / \Delta P C = Δ V /Δ P ) sharply elevates the work of breathing, leading to diaphragmatic fatigue and hypercapnic respiratory failure. Surfactant Deficiency (Prematurity)

  • |
  • High Alveolar Surface Tension (Laplace's Law)
  • |
  • Widespread Microatelectasis & Decreased FRC
  • |
  • Ventilation-Perfusion Mismatch & Hypoxemia
  • |
  • Capillary Shear Stress & Endothelial Injury
  • |
  • Exudation of Proteinaceous Fibrin Fluid
  • |
  • Hyaline Membrane Formation & Surfactant Inactivation
  • Clinical Manifestations and Diagnostic Radiography of RDS

Clinical signs of RDS typically appear immediately at birth or emerge within the first 4 to 6 hours of extrauterine life, progressively deteriorating over the subsequent 48 hours if untreated.

Cardinal Clinical Signs

Tachypnoea: Respiratory rate exceeding 60 breaths/min , representing a compensatory response to generate adequate minute ventilation in the presence of tiny tidal volumes.

Expiratory Grunting: The hallmark sign of RDS. Grunting is produced by dynamic vocal cord adduction during expiration against a closed glottis. This generates intrinsic positive end-expiratory pressure (auto-PEEP), which splints terminal bronchioles open and preserves end-expiratory alveolar volume.

Increased Work of Breathing: Prominent sternal, subcostal, and intercostal retractions. The highly compliant, cartilaginous chest wall of the preterm neonate collapses inward under the extreme negative intrathoracic pressures required to inflate stiff, non-compliant lungs.

Nasal Flaring: Reflex dilation of the alae nasi reduces upper airway resistance by up to 30%.

Cyanosis: Central cyanosis in room air, reflecting severe right-to-left intrapulmonary and intracardiac shunting.

Characteristic Chest Radiographic Findings

Chest radiography (CXR) confirms the diagnosis and differentiates RDS from transient tachypnoea of the newborn (TTN), meconium aspiration, and congenital diaphragmatic hernia:

Diffuse Reticulogranularity ("Ground-Glass" Appearance): Symmetric, fine punctate opacities distributed evenly across both lung fields, reflecting thousands of microatelectatic alveolar clusters interspersed with dilated alveolar ducts.

Prominent Air Bronchograms: Dark, branching, air-filled major bronchi standing out clearly against the surrounding radiodense, non-aerated lung parenchyma.

Hypoaeration (Low Lung Volumes): Bell-shaped thoracic contour with fewer than 8 posterior ribs visible above the dome of the right hemidiaphragm on an inspiratory film.

Progression to "White-Out": In severe, untreated cases, complete bilateral opacification obscures the cardiac margins and diaphragmatic domes.

Antenatal Corticosteroids (ACS)

Antenatal administration of maternal corticosteroids is the cornerstone preventive therapy for preterm lung disease, dramatically altering neonatal survival worldwide.

Indications and Regimens

Target Population: Under the European RDS consensus, offer a course when birth is highly likely within 7 days, from potential viability to before 34 weeks , with active neonatal care planned. Later-preterm use, including planned caesarean birth without labour, requires individual obstetric assessment of respiratory benefit and neonatal hypoglycaemia risk.

Standard Evidence-Based Regimens:

Betamethasone: 12 mg intramuscularly , two doses administered 24 hours apart .

Dexamethasone: 6 mg intramuscularly , four doses administered 12 hours apart .

Molecular Mechanism and Clinical Impact

Betamethasone and dexamethasone cross the placenta and promote structural and biochemical fetal lung maturation. Within fetal lungs, they bind intracellular glucocorticoid receptors in type II pneumocytes, stimulating transcription of surfactant proteins (SP-A, SP-B, SP-C) and enzymes in the CDP-choline phospholipid pathway. They also upregulate epithelial sodium channels (ENaC) , accelerate alveolar septation, and thin the pulmonary interstitial mesenchyme.

  • Outcome Impact of Antenatal Corticosteroids
  • Neonatal Mortality Reduced by ~30%
  • Respiratory Distress Syndrome (RDS) Reduced by ~35% to 40%
  • Intraventricular Haemorrhage (IVH) Reduced by ~50% (all grades and severe grades)
  • Necrotising Enterocolitis (NEC) Reduced by ~50%
  • Systemic Infection in First 48 Hours Reduced by ~45%

Tip

Maximum clinical benefit occurs when delivery takes place between 24 hours and 7 days after the first corticosteroid dose. The European RDS consensus allows a single repeat course before 32 weeks if preterm birth remains threatened and the first course was given at least 1–2 weeks earlier; repetition is not automatic. Routine weekly courses are contraindicated because they cause fetal growth restriction and reduced head circumference.

Non-Invasive Respiratory Support vs. Invasive Mechanical Ventilation

The management paradigm for preterm infants has shifted decisively from routine delivery room intubation toward early, non-invasive respiratory stabilization.

Early Continuous Positive Airway Pressure (CPAP)

The European Consensus Guidelines on RDS recommend that all spontaneously breathing preterm infants with respiratory distress should be started on nasal CPAP of 6 to 8 cmH2O immediately in the delivery room.

CPAP recruits atelectatic alveoli, establishes and maintains functional residual capacity, prevents alveolar end-expiratory collapse, stabilizes the compliant thoracic cage, and conserves endogenous surfactant.

Trials including COIN and SUPPORT support early CPAP as an alternative to routine intubation. SUPPORT found fewer days of mechanical ventilation, but no significant difference in its primary outcome of death or BPD. NeOProM combined trials of oxygen-saturation targets.

Target Oxygenation: During the first minutes after birth, use the age-specific transitional saturation targets in the ERC algorithm. After transition , the European RDS target for oxygen-treated extremely preterm infants is 90–94% , with alarms at 89% and 95% . Titrate oxygen to limit both hypoxaemia and oxygen toxicity; do not impose the maintenance target immediately at birth.

Exogenous Surfactant Replacement Therapy

Exogenous surfactant instillation directly restores alveolar surface tension, improves lung compliance, expands functional residual capacity, and decreases intrapulmonary shunting within minutes of administration.

Surfactant Preparations

Natural animal-derived surfactants are significantly more effective than synthetic products lacking surfactant-associated proteins:

Poractant Alfa (Porcine Lung Extract - Curosurf): Contains high concentrations of phospholipids and SP-B/SP-C. Administered at an initial dose of 200 mg/kg (2.5 mL/kg) . Clinical trials demonstrate that this initial 200 mg/kg dose achieves more rapid oxygenation improvement and significantly lower mortality compared to 100 mg/kg initial doses of bovine preparations.

Bovine Extracts: Beractant 100 mg/kg (4 mL/kg) and bovactant 50 mg/kg (1.2 mL/kg) have different recommended doses; do not interchange them.

Further doses may be needed for persistent RDS after other causes of deterioration are excluded. Repeat dose, interval and maximum number depend on the preparation; follow its product information.

Surfactant Administration Thresholds

According to European Consensus Guidelines:

Give surfactant for worsening RDS on non-invasive support. For infants >28 weeks , the 2025 European consensus suggests a threshold of FiO2 ≥0.30 on support at a mean airway pressure of ≥6 cmH2O , or lung-ultrasound evidence of surfactant need. In infants <28 weeks , consider selective prophylaxis within the first hour after stabilisation if early RDS signs are present.

Surfactant should be administered early in the disease course (ideally within the first 2 hours of life), as delayed administration after significant epithelial injury has occurred yields inferior outcomes.

Administration Techniques

LISA / MIST (Less Invasive Surfactant Administration / Minimally Invasive Surfactant Therapy):

Technique: While the infant breathes spontaneously on continuous nasal CPAP, a thin, flexible catheter (e.g., 16–18G vascular catheter or dedicated fine feeding tube) is guided through the vocal cords into the trachea under direct or video laryngoscopy. Surfactant is slowly instilled over 1 to 3 minutes, and the catheter is withdrawn immediately.

Advantages: The infant maintains spontaneous diaphragmatic breathing throughout the procedure. It completely avoids positive pressure mechanical ventilation via an endotracheal tube, reducing barotrauma, volutrauma, and the need for mechanical ventilation within the first 72 hours, while decreasing the incidence of BPD.

INSURE (INtubate - SURfactant - Extubate):

The infant is intubated with an endotracheal tube, surfactant is delivered via bolus, the infant is stabilized with brief manual or mechanical ventilation, and then extubated directly back to CPAP within 15 to 30 minutes.

Endotracheal Bolus with Ongoing Mechanical Ventilation:

Reserved for infants who are apnoeic, hemodynamically unstable, or failing non-invasive CPAP despite surfactant administration.

Bronchopulmonary Dysplasia (BPD) / Chronic Lung Disease of Prematurity

Bronchopulmonary Dysplasia represents the most frequent long-term pulmonary complication of extreme prematurity.

"Old" vs. "New" BPD Pathophysiology

Old BPD (Northway et al., 1967): Occurred in moderately preterm or term infants exposed to aggressive mechanical ventilation with high peak inspiratory pressures and prolonged hyperoxia. Characterized pathologically by severe airway injury, squamous metaplasia, marked peribronchial smooth muscle hypertrophy, alternating atelectasis and emphysematous bullae, and extensive parenchymal fibrosis.

New BPD (Jobe, 1999): Occurs in extremely preterm infants (<28 weeks gestation, birth weight <1,000 g) whose lungs are in the canalicular or early saccular stages of development. The hallmark is arrest of alveolar septation and pulmonary microvascular development . Histology demonstrates simplified, enlarged alveoli with reduced total surface area for gas exchange, a deficient capillary network, and variable dysmorphic pulmonary arterial remodeling predisposing to pulmonary hypertension.

Diagnostic Criteria and Severity Classification

The classic 2001 NICHD definition requires supplemental oxygen for at least 28 cumulative days . For infants born before 32 weeks, assess severity at 36 weeks postmenstrual age (PMA) or discharge, whichever occurs first, using the table below. This oxygen-based framework differs from the 2019 Jensen definition , which grades respiratory support at 36 weeks irrespective of oxygen exposure; nasal flow >2 L/min is grade 2 and invasive ventilation is grade 3.

  • Severity Grade Respiratory Support at 36 Weeks PMA
  • Mild BPD Breathing room air (21% O2)
  • Moderate BPD Requiring <30% supplemental oxygen
  • Severe BPD Requiring ≥30% supplemental oxygen and/or positive-pressure support (CPAP or invasive ventilation)
  • Evidence-Based Management and Prevention

Lung-Protective Ventilation: Utilize volume-targeted ventilation (VTV) targeting tidal volumes of 4 to 6 mL/kg to prevent volutrauma, combined with permissive hypercapnia (target pH 7.22–7.35, PaCO2 50–65 mmHg / 6.5–8.5 kPa).

Caffeine Citrate: Initiated within the first 72 hours of life (loading dose 20 mg/kg, maintenance 5–10 mg/kg/day). Caffeine stimulates respiratory drive and facilitates extubation. In the CAP trial , positive airway pressure was stopped a median one week earlier , and BPD was reduced; follow-up showed improved survival without neurodevelopmental disability at 18–21 months .

Postnatal Corticosteroids: High-dose systemic dexamethasone causes neurotoxicity and significantly increases the incidence of cerebral palsy. Low-dose dexamethasone (e.g., DART protocol : cumulative dose 0.89 mg/kg over 10 days) is restricted strictly to ventilator-dependent infants after 1 to 2 weeks of life who cannot be weaned from mechanical ventilation and face a very high risk of developing fatal or severe BPD.

Inhaled Therapies and Diuretics: Early inhaled budesonide reduced BPD in trials, but follow-up raised concern about increased mortality; routine prevention is not recommended. Routine bronchodilators and chronic diuretics have not demonstrated durable benefit and should not be used routinely.

Post-Discharge Respiratory Syncytial Virus (RSV) Immunoprophylaxis

Infants with bronchopulmonary dysplasia possess restricted airway calibers and abnormal pulmonary vascular architecture. Infection with Respiratory Syncytial Virus (RSV) precipitates severe bronchiolitis, respiratory failure, prolonged ICU admission, and death.

Prophylactic Regimens

Palivizumab: A humanized IgG1 monoclonal antibody directed against the conserved antigenic site of the RSV fusion (F) glycoprotein, blocking viral cell entry and syncytium formation.

Dosing: 15 mg/kg intramuscularly administered every 30 days during the winter epidemic season (up to a maximum of 5 doses).

European Licensed Indications: Palivizumab is indicated for infants born at ≤35 weeks who are <6 months old at RSV-season onset; children <2 years needing BPD treatment within the previous 6 months ; and children <2 years with haemodynamically significant congenital heart disease. National programmes determine clinical eligibility and choice of prophylaxis; the older AAP <29-week criterion is not a pan-European rule.

Nirsevimab: A recombinant human IgG1κ monoclonal antibody targeting the prefusion conformation of the RSV F protein. Engineered with a triple-amino-acid substitution in the Fc region that prolongs its elimination half-life to ~60 to 70 days. A single intramuscular dose provides season-long protection (at least 5 months), significantly simplifying compliance and reducing RSV hospitalizations across Europe.